** Shares of drug developer KOOL.O rise 23% to $3.43
** Co says its subsidiary ThermoGenesis Corp received Health
Canada approval of its next-generation AXP II system for cord
blood processing urn:newsml:reuters.com:*:nPn3RLKRa
** AXP II was cleared by the FDA in Nov. 2018
** The product provides automated, rapid and reproducible
harvesting of stem cells from collected units of umbilical cord
blood and is used by cord blood banks
** Up to Monday's close, stock had fallen 47.3% over the
past year
(Reporting by Tamara Mathias in Bengaluru)
((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))